Sanford-Burnham researchers identify new target for melanoma treatment
- Posted: September 17, 2013
Scientists at Sanford-Burnham Medical Research Institute announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1 (PDK1), plays an essential role in the development and progression of melanoma. The finding, available in the advanced online publication of Oncogene, offers a new approach to treating this life-threatening disease.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.